Illumina’s accelerator selects next wave of genomics newcos

The Illumina Accelerator picked seven genomics start-ups, among them five life sciences companies developing technologies ranging from direct-to-consumer single-cell transcriptomics to AI-derived multitargeted therapies.

The funding cycle is the thirteenth for the accelerator’s San Francisco Bay Area site and third for its Cambridge, U.K.-based center. Since its founding in 2014, the Illumina Accelerator has invested in 61 genomic start-ups, which have gone on to raise more than $1 billion in aggregate venture capital. ...